IMPACT-CABG Trial: Implantation of CD133+ Stem Cells in Patients Undergoing Coronary Bypass Surgery—Presentation of the First Treated Patient

• Published in: Case reports in transplantation Vol. 2011; no. 2011; pp. 1 - 3
• Main Authors: Roy, Denis-Claude, Prieto, Ignacio, Mansour, Samer, Stevens, Louis Mathieu, Forcillo, Jessica, Noiseux, Nicolas
• Format: Journal Article
• Language: English
• Published: Cairo, Egypt Hindawi Publishing Corporation 01.01.2011; Wiley
• Subjects: Case Report
• ISSN: 2090-6943; 2090-6951
• DOI: 10.1155/2011/685394

The IMPACT-CABG study is the first Canadian randomized-controlled phase II clinical trial aiming to assess the effect of intramyocardial (IM) injections of CD133+-selected stem cells in patients referred for coronary artery bypass graft (CABG) with a “chronic” myocardial infarction and persistent left ventricular dysfunction. Patients are followed for 2 years with different imaging techniques including the stress magnetic resonance to evaluate the global and regional myocardial viability. Before the beginning of the randomization, the 5 first patients are treated in an open-label fashion to assess safety and feasibility of the IM CD133+ injections. Herein, we report the first Canadian patient treated with IM injection of CD133+ cells during CABG surgery as part of the IMPACT-CABG trial.